Vertex starts cystic fibrosis study

By Elaine Rigoli

Tampa, Fla., May 17 - Vertex Pharmaceuticals, Inc. has started a phase 1 clinical study for VX-770, an oral drug candidate that specifically targets a key mechanism underlying cystic fibrosis.

The study will evaluate the safety, tolerability and pharmacokinetics of escalating single and multiple doses of VX-770 in healthy volunteers and also will evaluate single doses of VX-770 in patients with cystic fibrosis, the company said in a news release.

In March, Vertex and Cystic Fibrosis Foundation Therapeutics, Inc. entered into a collaboration to accelerate clinical development of VX-770. Vertex retains worldwide rights to develop and commercialize VX-770.

Vertex also announced that the Food and Drug Administration has granted fast-track designation to VX-770.

Located in Cambridge, Mass., Vertex is a biotechnology company that develops and commercializes products focused on viral diseases, inflammation, autoimmune diseases and cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.